Efforts to identify and annotate cancer driver genetic lesions have been focused primarily on the analysis of protein-coding genes; however, most genetic abnormalities found in human cancer are located in intergenic regions. Here we identify a new long range-acting MYC enhancer controlled by NOTCH1 that is targeted by recurrent chromosomal duplications in human T cell acute lymphoblastic leukemia (T-ALL). This highly conserved regulatory element, hereby named N-Me for NOTCH MYC enhancer, is located within a broad super-enhancer region +1.47 Mb from the MYC transcription initiating site, interacts with the MYC proximal promoter and induces orientation-independent MYC expression in reporter assays. Moreover, analysis of N-Me knockout mice demonstrates a selective and essential role of this regulatory element during thymocyte development and in NOTCH1-induced T-ALL. Together these results identify N-Me as a long-range oncogenic enhancer implicated directly in the pathogenesis of human leukemia and highlight the importance of the NOTCH1-MYC regulatory axis in T cell transformation and as a therapeutic target in T-ALL. Supplementary Tables 1 and 2). We identified no duplications in this region in 258 non-T-ALL hematologic tumors, and no germline copy number variant polymorphisms encompassing this area have been reported. Moreover, analysis of normal (remission) DNA confirmed the somatic origin of these copy number alterations in all four cases with available material (Supplementary Fig. 1 ). Notably, chromatin immunoprecipitation followed by next-generation sequencing (ChIPseq) analysis of NOTCH1 chromatin binding sites in HPB-ALL T-ALL cells revealed a prominent 1-kb NOTCH1 peak in chromosome 8q24 located within the common 40-kb segment duplicated in T-ALL (Fig. 1a) . A survey of NOTCH1 and RBPJ ChIP-seq data generated in the CUTLL1 T-ALL cell line 17 confirmed the presence of high levels of NOTCH1 and RBPJ binding at this site ( Fig. 1b and Supplementary Fig. 2 ). Multispecies DNA sequence alignment revealed remarkable conservation of this region between mammals, birds and reptiles (Fig. 1b) , with 88.6% nucleotide identity between the 500-bp human and mouse sequences centered on the NOTCH1 peak compared with an average conservation of 44% nucleotide identity along the 1.4-Mb gene desert telomeric to MYC. Consistently, analysis of Notch1 ChIP-seq data in G4A2 mouse T-ALL cells 18, 19 revealed matching Notch1 and Rbpj binding peaks located +1,27 Mb from the Myc transcription initiation site ( Fig. 1c and Supplementary Fig. 2 ).
a r t i c l e s T-ALL is an aggressive hematologic malignancy resulting from the transformation of immature T cell progenitor cells 1 in which activation of transcription factor oncogenes and deregulation of transcriptional regulatory networks have particularly prominent roles [1] [2] [3] [4] [5] . In this context, activating mutations in NOTCH1, a ligand-activated transcription factor oncogene, are found in over 60% of human TALLs 6, 7 . Mechanistically, NOTCH1 mutations found in T-ALL result in increased NOTCH1 signaling, which promotes T cell transformation through the physiologic functions of the NOTCH1 receptor in the thymus, where ligand-induced NOTCH signaling drives hematopoietic progenitors into the T cell lineage and promotes thymocyte development [7] [8] [9] . Both the physiologic and oncogenic effects of NOTCH1 require translocation of the intracellular portion of the NOTCH1 receptor to the nucleus, where it activates gene expression in association with the recombination signal binding protein for immunoglobulin κJ region (RBPJ) DNA binding protein 7, 10, 11 . Gene expression studies have identified NOTCH1 as a key regulator of cell growth in T-ALL lymphoblasts directly controlling numerous genes that are involved in cell growth and metabolism 12 . The importance of understanding the hierarchy of the oncogenic NOTCH1 transcriptional programs is highlighted by the proposed role of small-molecule γ-secretase inhibitors, which block the cleavage of NOTCH1 and the release of intracellular NOTCH1 from the membrane and effectively suppress NOTCH signaling, as targeted therapies for the treatment of T-ALL 7 .
Recently, numerous studies have dissected the mutational landscape of T-ALL, resulting in the identification of numerous oncogenes and tumor suppressors implicated in T cell transformation 1, 4, 13 . However, and most intriguingly, most genetic abnormalities found in human cancer are located in intergenic regions 14 , whose role in cancer development, if any, remains poorly understood. Here we hypothesize that recurrent cancer-associated intergenic mutations, amplifications and deletions may implicate strong transcriptional regulatory sequences that are responsible for the activation of oncogenic factors downstream of key T-ALL transcription factor oncogenes such as NOTCH1.
RESULTS

Amplification of a MYC NOTCH1-occupied enhancer in T-ALL
To assess the role of intergenic copy number alterations in the pathogenesis of T-ALL, we analyzed array comparative genomic hybridization data from 160 T-ALL cases. This analysis identified recurrent focal duplications at chromosome 8q24 in 8 out of 160 (5%) cases in an area devoid of protein-coding genes located +1,427 kb downstream of MYC (Fig. 1a) , a critical oncogene in the pathogenesis of NOTCH1-induced T-ALL 12, 15, 16 (Fig. 1a, Supplementary Fig. 1 and T-ALL cells. These analyses confirmed high levels of NOTCH1 binding at this site and revealed bona fide active enhancer features associated with this region, including occupancy and high levels of P300 (also called EP300) and histone H3 Lys4 monomethylation (H3K4me1) with low levels of H3K4 trimethylation (H3K4me3) ( Fig. 1d and Supplementary Fig. 3 ). Moreover, inspection of Encyclopedia of DNA Elements (ENCODE) data in this region revealed that this NOTCH1-occupied enhancer sits within a 20-kb segment containing high levels of H3K27 acetylation (H3K27ac) and H3K4me1 ( Fig. 1e) , features that are characteristically associated with highly dynamic long-range super-enhancer regulatory sequences 20 . In addition, extended examination of ENCODE data revealed that H3K27ac in this area is selectively present in DND-41 cells, a T-ALL cell line that harbors a highly active mutant form of NOTCH1 (ref. 6 ), but not in primary CD20 + B cells or cell lines derived from a variety of other hematopoietic and nonhematopoietic tissues and cell lines ( Fig. 1f and Supplementary Fig. 3 ). On the basis of these results, we proposed that this +1. 4 Mb MYC NOTCH1-occupied enhancer-hereby named N-Me for NOTCHbound MYC enhancer-could function as an important regulatory element driving the activation of MYC downstream of NOTCH1 in T-ALL. Consistent with this hypothesis, chromatin configuration 3C (chromosome conformation capture) analysis of the MYC locus demonstrated the association of this enhancer with proximal regulatory sequences in the MYC promoter (Fig. 2a) . Moreover, luciferase reporter assays showed strong, orientation-independent activation of reporter constructs containing this enhancer in association with a −2.5 kb MYC proximal promoter 21 in JURKAT T-ALL cells, which express high levels of constitutively active NOTCH1 protein 22 , but not in Daudi and Raji B-lineage cells ( Fig. 2b and Supplementary  Fig. 4 ). Human N-Me-driven reporter activity in JURKAT cells was suppressed by inhibition of NOTCH1 signaling with the γ-secretase inhibitor DBZ and was decreased by mutation of N-Me RBPJ binding sites (Fig. 2b,c and Supplementary Fig. 5 ). Conversely, reporter activity in these assays was increased by the introduction of two tandem copies of the human N-Me enhancer, demonstrating a quantitative, dose-dependent increase of MYC promoter activity by this regulatory sequence (Fig. 2d) . We obtained similar results in reporter assays testing the activity and NOTCH signaling dependency of the mouse N-Me enhancer (Fig. 2e,f and Supplementary Fig. 5 ). Overall these results identify the N-Me enhancer as a recurrently duplicated long-range regulatory element that is involved in the control of MYC expression downstream of NOTCH1 in T-ALL.
The N-Me enhancer is required for thymocyte development To test the specificity and functional relevance of the N-Me enhancer in T cell development and transformation, we used homologous recombination in mouse embryonic stem cells to generate N-Me knockout and conditional knockout mice (Supplementary Fig. 6 ). N-Me knockout mice were born at Mendelian frequencies (Supplementary Table 3) , survived perinatally and showed normal postnatal development without apparent behavioral abnormalities or defects in body size (Supplementary Fig. 7) . Notably, anatomical and histological analysis of the mice at 6 weeks of age revealed marked selective reduction in thymus size and cellularity in N-Me knockout animals compared to littermate controls ( Fig. 3a-d) . Despite preservation of thymus size and architecture, thymocyte counts were partially reduced in N-Me heterozygous knockout mice (Fig. 3a-d) . Immunohistochemical analysis of N-Me knockout thymi showed reductions in markers of proliferation (Ki67 and phosphorylated histone H3) with no apparent increase in apoptosis (as assessed by cleaved caspase 3) (Fig. 3e) . In addition, analysis of T cell populations in the spleen and lymph nodes of N-Me knockout animals showed a marked reduction in the number of mature CD4 + and CD8 + T cells (Supplementary Fig. 7) . Analysis of bone marrow hematopoietic populations revealed normal numbers of B cell precursors, myeloid progenitors, megakaryocytes and hematopoietic stem cells ( Supplementary Fig. 7) . Moreover, histological analysis of multiple tissues, including those in which NOTCH signaling has important developmental roles, such as breast epithelium, skin and intestine, showed no alterations ( Supplementary Fig. 7 ), and RT-PCR analysis showed no effects of N-Me deletion on Myc expression (Supplementary Fig. 7 ). (Fig. 4f) . Consistently, transplantation of CD45.2 N-Me knockout bone marrow hematopoietic progenitors into lethally irradiated CD45.1 mice effectively reconstituted B cell and myeloid lineages but not T cell development (Fig. 4g) . Moreover, retroviral expression of MYC in N-Me knockout hematopoietic progenitors restored their capacity to reconstitute T cell development when transplanted into immunodeficient NRG mice (Fig. 4h) .
N-Me is required for NOTCH1-induced T cell leukemogenesis
Given the important role of NOTCH1-induced MYC upregulation in the pathogenesis of T-ALL, we hypothesized that deletion of the N-Me enhancer could disrupt NOTCH1-induced leukemogenesis. To test this possibility, we transplanted isogenic C57BL/6 mice with wild-type or N-Me heterozygous or homozygous knockout hematopoietic progenitors infected with retroviruses driving the expression of an . P values were calculated using two-tailed Student's t test. # P = 0.07, *P ≤ 0.05, **P ≤ 0.01, *** P ≤ 0.005. NS, not significant. npg a r t i c l e s oncogenic constitutively active form of NOTCH1 (∆E-NOTCH1) 10 . Consistent with previous reports 23 , mice transplanted with ∆E-NOTCH1-infected wild-type cells showed a transient early increase in the frequency of CD4 + CD8 + double-positive cells in peripheral blood 3 weeks after transplant (Fig. 5a) , which anticipated the development of overt T-ALL 3 weeks later (Fig. 5b,c) . Mice transplanted with ∆E-NOTCH1-expressing N-Me heterozygous knockout progenitors showed a blunted increase of CD4 + CD8 + double-positive cells in peripheral blood and delayed tumor development (P < 0.01) (Fig. 5a-c) , whereas animals transplanted with ∆E-NOTCH1-expressing N-Me homozygous knockout cells failed to develop CD4 + CD8 + double-positive cells in peripheral blood and remained leukemia free 9 weeks after transplant (P < 0.001) (Fig. 5a-c) .
To explore the pathogenic role of N-Me-mediated Myc expression in NOTCH1-induced leukemia tumor maintenance, we generated ∆E-NOTCH1-induced T-ALL tumors from wild-type (Rosa26TM-Cre N-Me +/+ ) and tamoxifen-inducible conditional heterozygous (Rosa26TM-Cre N-Me flox/+ ) and homozygous (Rosa26TM-Cre N-Me flox/flox ) N-Me knockout hematopoietic progenitors. In these experiments, mice transplanted with ∆E-NOTCH1-expressing wildtype and tamoxifen-inducible heterozygous and homozygous conditional N-Me knockout cells developed NOTCH1-induced T-ALLs with identical kinetics and immunophenotypes ( Supplementary  Fig. 8) . To test the effects of N-Me deletion in established leukemia, we then injected wild-type and tamoxifen-inducible heterozygous and homozygous conditional N-Me knockout T-ALL lymphoblasts into secondary recipients and treated them with vehicle only or tamoxifen 3 days after transplant. In these experiments, tamoxifen-induced activation of Cre recombinase had no effect on leukemia progression in mice harboring wild-type tumor cells compared with controls (Fig. 6a) . In contrast, tamoxifen-induced deletion of one copy of the N-Me enhancer in Rosa26TM-Cre N-Me flox/+ tumors or two copies in Rosa26TM-Cre N-Me flox/flox leukemias resulted in antileukemic effects and improved survival (Fig. 6b,c) . Analysis of Rosa26TM-Cre N-Me flox/+ tumor cells recovered during disease progression after tamoxifen treatment showed heterozygous deletion of the N-Me enhancer (Supplementary Fig. 9 ), whereas analysis of tamoxifen-treated progressing Rosa26TM-Cre N-Me flox/flox tumors demonstrated retention of one (2/9) or both (5/9) copies of the N-Me flox allele (Supplementary Fig. 9 ). We then performed limited dilution transplantations of conditional NOTCH1-induced N-Me knockout tumor cells and analyzed the effects N-Me inactivation by tamoxifen treatment on leukemia-initiating cells. In this experiment, genetic inactivation of the N-Me enhancer resulted in an ~170-fold reduction in the frequency of leukemia-initiating cells (Supplementary Fig. 10) . Overall, these results show a strong dose-dependent effect of the NMe enhancer in NOTCH1-induced tumor initiation and maintenance and in leukemia-initiating cell activity.
To better assess the mechanisms mediating the antileukemic effects of N-Me inactivation, we then analyzed the cellular and transcriptional phenotypes of N-Me conditional inducible knockout T-ALL cells after tamoxifen treatment. In this setting, N-Me deletion in T-ALL cells (Supplementary Fig. 11 ) resulted in unloading of RNA polymerase II (Pol II) from the Myc transcription start site (Fig. 6d) and markedly reduced Myc RNA and protein expression levels (Fig. 6e,f) . At the cellular level, N-Me inactivation caused decreased cell proliferation with G1 cell cycle arrest (Fig. 6g) . Notably, retroviral expression of MYC rescued the growth defect associated with genetic deletion of N-Me in NOTCH1-driven N-Me conditional knockout tumor cells (Fig. 6h) . Gene expression profiling analysis showed that N-Me inactivation resulted in effective downregulation of Myc-induced gene expression programs (Fig. 6i,j) and gene expression signatures associated with cell growth and proliferation (Supplementary Table 4) .
DISCUSSION
NOTCH1 has a central role in the pathogenesis of T-ALL 24 and drives an oncogenic transcriptional program that promotes cell growth proliferation and survival in T-ALL lymphoblasts. Importantly, the oncogenic effects of NOTCH1 are closely linked to activation of the MYC oncogene 12, 15, 16 The P values in a and b were calculated using two-tailed Student's t test. ***P ≤ 0.005. The P values in c were calculated using the log-rank test. **P ≤ 0.01, ***P ≤ 0.005. expression downstream of NOTCH1 in T-ALL remain incompletely understood. Here we report the identification and functional characterization of N-Me, a T cell-specific long-range regulatory sequence driving MYC expression downstream of NOTCH1 in T-ALL. This regulatory element, located +1,427 kb downstream of MYC in humans and +1.27 kb downstream of the Myc locus in mice, has histone marks associated with active enhancers, interacts with MYC proximal regulatory sequences and sits within a broad area of H3K27ac that was characterized recently as a T cell-specific super-enhancer 25 .
Transcriptional deregulation of MYC expression has an important role in the pathogenesis of multiple cancers, and the chromosome 8q24 region proximal to the MYC gene is a well-established risk locus for epithelial tumors [26] [27] [28] [29] [30] . Most of the genetic variants associated with cancer risk at 8q24 are located in a 500-kb gene desert region located approximately 200 kb centromeric of the MYC gene. This region contains multiple enhancer regulatory sequences 31 , which physically associate the MYC promoter using long-range chromatin loops 32 . Most notably, rs6983267, an enhancer-associated colon cancer risk allele variant in this region, has been shown to influence MYC expression downstream of β-catenin-transcription factor 4 (TCF4) 33 . Moreover, genetic deletion of the enhancer containing this regulatory element in the gut results in partial reduction of Myc expression in intestinal crypts and confers protection from intestinal tumorigenesis in Apc min mutant mice, which develop multiple spontaneous intestinal adenomas as result of a loss-of-function mutation in the Apc tumor suppressor gene 34 . In contrast, no cancer-associated single-nucleotide variants have been mapped to the larger gene-free region telomeric to the MYC gene where N-Me resides. However, a recent report identified The P values in a-c were calculated using log-rank test. ***P ≤ 0.005. NS, not significant. The P values in d, e, g and h were calculated using two-tailed Student's t test. ***P ≤ 0.005. npg a r t i c l e s a broad regulatory area of about 100 kb located 1.7 Mb telomeric to the Myc gene, 400 kb downstream of N-Me 35 . This Myc regulatory region contains multiple enhancers that are active in myeloid cells but not the thymus and is duplicated in about 3% of acute myeloid leukemias 35 . Genetic deletion of N-Me in mice resulted in reduced thymic cellularity and cell proliferation, demonstrating a critical role of this regulatory element in the homeostasis of immature T cells. N-Menull mice showed severe reductions in the number of CD4 + CD8 + double-positive cells and the subsequent single-positive CD4 + and CD8 + populations. These phenotypes recapitulate those reported in T cell-specific Myc conditional knockout mice (Lck-Cre Myc flox/flox ) 36 . Given the proposed role of NOTCH1 signaling in hematopoietic stem cells and non-lymphoid tissues such as breast epithelium, we thoroughly examined a potential role for N-Me in the control of Myc expression in these tissues. However, consistent with a T cell-specific role of N-Me in the control of Myc expression, we detected no alterations in any cellular compartment other than T cells. These results suggest that NOTCH1-controlled enhancers that remain to be discovered may regulate Myc expression in breast epithelium and hematopoietic stem cells.
The requirement for N-Me-mediated upregulation of Myc expression downstream of Notch1 was even more apparent in the context of leukemia initiation, where loss of one and two copies of N-Me delayed and abrogated tumor development by oncogenic NOTCH1, respectively. In addition, N-Me was also required for the maintenance of NOTCH1-induced leukemias, as secondary deletion of one copy of N-Me in established tumors resulted in a marked delay in tumor progression, and loss of two copies effectively abrogated leukemia propagation and the self-renewal capacity of leukemia-initiating cells. These results are consistent with the well-established quantitative effects of MYC expression in other tumor settings. Loss of one copy of Myc has been shown to attenuate intestinal tumorigenesis 37 , and homozygous deletion of Myc completely abrogates tumor development induced by loss of Apc in the gut 38 .
Several lines of evidence support a role for loss of Myc expression as the primary driver in the developmental and tumor phenotypes associated with N-me loss. In this regard, we observed marked reductions in Myc expression in developing T cells from N-Me knockout mice and in T-ALL lymphoblasts after N-Me inactivation. Moreover, retroviral expression of Myc restored T cell lymphopoiesis from NMe-deficient hematopoietic progenitors and rescued the defects in leukemia cell growth induced by secondary deletion on N-Me in NOTCH1-induced T-ALL cells. In addition, MYC inactivation has been associated with a global decrease in transcriptional activity, with a particularly pronounced downregulation of genes involved in growth, proliferation and metabolism [39] [40] [41] , which were highly enriched in the gene expression signatures associated with N-Me loss in T-ALL.
The generation of the N-Me conditional knockout model presented here was also useful in analyzing the specific role of this enhancer in transcriptional control. Thus, even though in some cases enhancerpromoter interactions have been implicated in the regulation of transcription by promoting the release of RNA Pol II pausing 42 , deletion of N-Me in T-ALL lymphoblasts resulted in unloading of RNA Pol II at the Myc transcription initiation site without any apparent increase in RNA Pol II pausing.
Overall, our results identify the N-Me regulatory sequence as a critical mediator of NOTCH1-induced MYC expression that is required for T cell development and transformation and substantiates a pathogenic role for chromosomal duplications targeting this enhancer in the pathogenesis of T-ALL.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes.
Microarray gene expression and ChIP-seq data are available in Gene Expression Omnibus (GEO) under accession codes GSE57988 and GSE58406. Array comparative genomic hybridization data have been deposited in ArrayExpress under accession code E-MTAB-2775.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ChIP. We performed ChIP using the Agilent Mammalian ChIP-on-chip protocol as described previously 12, 47 . Briefly, 10 8 HPB-ALL cells were fixed with formaldehyde in a final concentration of 1% for 10 min at room temperature. We quenched the crosslinking reaction with a 2.5 M glycine solution, and the cells were then centrifuged, washed once with ice-cold PBS and lysed. Cell nuclei were resuspended in lysis buffer (10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM ethylene glycol tetraacetic acid (EGTA), 0.1% sodium deoxycholate and 0.5% N-lauroylsarcosine) and fragmented to a 150-to 300-bp size using a Bioruptor sonicator (Diagenode). We incubated fragmented chromatin overnight at 4 °C with magnetic beads (Dynal) loaded with 1 mg of the following specific antibodies: anti-NOTCH C-20 (sc-6014, Santa Cruz Biotechnology), anti-NOTCH1 Val1744 (2421, Cell Signaling), anti-p300 (sc-585, Santa Cruz Biotechnology), anti-H3K4me1 (ab8895, Abcam) and anti-H3K4me3 (ab1012, Abcam).
For RNA Pol II ChIP, N-Me flox/flox ; RosaTM-Cre tg/+ tumor cells were treated in vitro with ethanol or tamoxifen to induce N-Me deletion. 48 h later, 10 7 cells from both conditions were processed the same way as described in the previous paragraph, and the fragmented chromatin was incubated overnight at 4 °C with magnetic beads loaded with 5 mg of the RNA Pol II antibody (sc-899, Santa Cruz Biotechnology).
We washed chromatin-antibody-bead complexes seven times with RIPA buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-KOH, pH 7.6, 0.5 M LiCl, 1 mM EDTA, 1% IGEPAL (I8896, Sigma-Aldrich) and 0.7% sodium deoxycholate) and once with Tris-EDTA (TE) buffer containing 50 mM NaCl. Then we eluted the chromatin from the beads with elution buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA and 1% SDS) and reversed the crosslink by incubation at 65 °C overnight. We purified DNA fragments with phenol-chloroform and ethanol precipitation. We tested the enrichment of specific immunoprecipitated DNA fragments by quantitative PCR as previously described 12, 47 .
ChIP-seq. ChIP-seq for NOTCH1 in HPB-ALL cells was performed using chromatin immunoprecipitates generated as described above and further fragmented to a 100-bp average size using a Covaris sonicator. All preparations of libraries for sequencing and the sequencing itself were performed according to the SOLiD3 System protocols. For library preparation, we performed adaptor ligation and purification, and the resulting DNA was amplified for 15 cycles. The libraries were then sequenced using 50-bp read lengths on a SOLiD3 instrument (Life Technologies).
We recovered 17,530,449 reads and 9,591,524 unique reads (defined by a unique sequencing read start site) that mapped exactly once to the hg19 human genome from the NOTCH1 ChIP-seq library, as well as 4,954,605 reads and 4,894,225 unique reads from the input control DNA library.
ChIP-seq and conservation analysis. We used the HOMER (hypergeometric optimization of motif enrichment) software suite 48 to estimate the ChIP fragment density at each position in the human genome for the HBP-ALL NOTCH1 ChIP-seq data. We also analyzed ENCODE-generated ChIP-seq data 49 and the following publicly available ChIP-seq results: CUTLL1 NOTCH1 ChIP-seq (GEO GSM732903) 18 , CUTLL1 RBPJ ChIP-seq (GEO GSM732905) 18 , G4A2 NOTCH1 ChIP-seq (GEO GSM732916) 18 and G4A2 RBPJ ChIP-seq (GEO GSM732917) 18 .
We used the model-based analysis of ChIP-seq (MACS) algorithm 50 to call ChIP-seq peaks, and the top-scoring intergenic peak was detected at chr8:130,180,065-130,180,972 (hg19), which aligns to the mouse genome (mm10) at chr15:63,255,515-63,256,347 (80.2% of bases, 100.0% of span).
The conservation track in Figure 1b shows a subset of the 100 vertebrates genomic sequence alignment as produced by the UCSC Genome Browser based on the MULTIZ algorithm 51 .
Quantitative 3C analysis. We performed 3C analysis of chromatin interactions as described previously 52 with some modifications. Briefly, HPB-ALL cells were crosslinked with formaldehyde in a final concentration of 1% for 10 min at room temperature. We quenched the crosslinking reaction with a 2.5 M glycine solution, and the cells were then centrifuged, washed once with ice-cold PBS and lysed. We digested cell nuclei overnight at 37 °C with the HindIII restriction enzyme. After digestion, the resulting fragments were highly diluted and ligated first for 4 h at 16 °C and then for 30 min at 37 °C. After ligation, the DNA was treated with proteinase K and de-crosslinked overnight at 65 °C. We cleaned and purified the DNA fragments by phenol-chloroform extraction and ethanol precipitation and resuspended them in 10 mM Tris, pH 7.5. The resulting 3C template was used to perform quantitative PCR using primers flanking the HindIII restriction sites located in the regions of interest within the MYC locus and in the vicinity of the N-Me enhancer in the 7300 quantitative PCR instrument (Applied Biosystems).
Luciferase reporter assays. We performed reporter assays using a pBV-Luc −2.5 kb MYC promoter luciferase construct 21 alone and coupled with upstream human and mouse N-Me enhancer sequences cloned in the forward and reverse orientations. In these assays, we electroporated in JURKAT cells with a Gene Pulser MXcell electroporator (Bio-Rad) using MYC luciferase reporter constructs together with a plasmid driving the expression of the Renilla luciferase gene (pCMV-Renilla) used as an internal control and treated them with DMSO or DBZ (250 nM) to inhibit NOTCH signaling. We measured luciferase activity 72 h after electroporation with the Dual-Luciferase Reporter Assay kit (Promega).
Mice and animal procedures. All animals were maintained in specific pathogen-free facilities at the Irving Cancer Research Center at Columbia University Medical Campus. Animal procedures were approved by the Columbia University Institutional Animal Care and Use Committee.
To generate N-Me conditional knockout mice, we introduced LoxP sites at mouse genomic (GRCm38/mm10) positions 63,255,283 and 63,256,404 flanking the mouse N-Me enhancer together with a neomycin selection cassette flanked by Frt sites by homologous recombination in C57BL/6 embryonic stem cells. We generated chimeras in C57BL/6 albino blastocysts using three independent targeted embryonic stem cell clones identified by PCR analysis and verified by Southern blot. We verified germline transmission in the offspring of highly chimeric male mice crossed with C57BL/6 albino females. To remove the neomycin selection cassette, we crossed mice harboring the targeting construct with a Flp germline deleter line (B6.129S4-Gt(ROSA)26Sortm1(FLP1)Dym/RainJ, the Jackson Laboratory). To generate mice carrying an N-Me deletion, we first crossed mice harboring this resulting conditional N-Me-targeted allele with a Cre germline deleter line (B6. C-Tg(CMV-cre)1Cgn/J, the Jackson Laboratory) and then crossed the resulting mice with wild-type C57BL/6 animals to breed out the CMV-cre allele. To generate conditional inducible N-Me knockout mice, we bred animals harboring the conditional N-Me targeted allele with ROSA26TM-Cre tg/+ mice, which express a tamoxifeninducible form of the Cre recombinase from the ubiquitous Rosa26 locus 53 .
npg
Phenotypic characterization of N-Me knockout mice included male and female mice and isogenic age-and gender-matched controls without blinding.
For secondary deletion of N-Me using tamoxifen-induced activation of Cre recombinase, in vivo animals were randomly assigned to the vehicle or tamoxifen groups without blinding.
Mammary epithelial cell isolation. To determine the specific estrus stage and, thus, the concomitant mammary gland developmental phase, we analyzed female mice for the presence of leukocytes, cornified epithelial cells and nucleated epithelial cells in vaginal smears as described previously 54 . To purify mammary epithelial cells, mammary glands were dissected, mechanically disrupted and digested using a digestion solution composed by DMEM-F12, 100 units/ml penicillin-streptomycin, 2 mg/ml collagenase A and 100 units/ml hyaluronidase for 4 hours at 37 °C. After digestion, we washed the mammary epithelial cells in PBS solution and recovered them by centrifugation.
Mammary gland whole-mount preparations and carmine red staining. For whole-mount preparations, we dissected mouse mammary glands, fixed them in 4% paraformaldehyde for 1 h and stained them with carmine red (C1022, Sigma-Aldrich) overnight at room temperature. After carmine red staining, we dehydrated the stained tissues in increasing concentrations of ethanol (70, 95 and 100%) and ultimately fixed them in xylene.
Immunohistochemistry. We performed immunohistochemical stainings following standard protocols using polyclonal antibodies to Ki67 (1:1,000, 15580, Abcam), phosphorylated histone H3 (1:200, 9701, Cell Signaling Technology) and cleaved caspase 3 (1:2,000, 5AE1, Cell Signaling Technology).
Generation of NOTCH1-induced leukemias.
To generate NOTCH1-induced T-ALL tumors in mice, we performed retroviral transduction of bone marrow cells enriched in lineage (Lin)-negative cells isolated from female mice using magnetic beads (Lineage Cell Depletion Kit, Miltenyi Biotec) with an activated form of the NOTCH1 oncogene (∆E-NOTCH1) 10 and transplanted them by intravenous injection into lethally irradiated female isogenic recipients as described previously 55 .
Flow cytometry analysis of hematopoietic populations. Single-cell suspensions of total bone marrow cells from 6-week-old wild-type and N-Me heterozygous and homozygous knockout littermates were prepared by crushing the leg bones and passing cells through a 40-µm filter. Single-cell suspensions of thymocytes were obtained by pressing one thymic lobe through a 40-µm filter. For flow cytometry-based analysis of bone marrow stem and progenitor populations and discrete stages of T cell development, cells were stained with anti-mouse fluorochrome-conjugated antibodies as follows (clone names are provided in parentheses): CD8-α phycoerythrin (PE)-Cy7 (1:800, 53-6.7),Bone marrow reconstitution experiments. We isolated bone marrow lineagenegative cells from N-Me +/+ , N-Me +/− and N-Me −/− CD45.2-expressing mice using magnetic beads (Lineage Cell Depletion kit, Miltenyi Biotec) following the manufacturer's guidelines and then transplanted them into lethally irradiated CD45.1 C57BL/6 female mice (Taconic). 6 weeks after transplant, hematologic reconstitution of myeloid lineage, B cell lineage and T cell lineage was assessed by peripheral blood staining with the specific antibodies mentioned above and analysis in a FACSCanto flow cytometer using FACSDiva (BD Biosciences).
For the Myc rescue experiment in vivo, we isolated bone marrow lineagenegative cells from N-Me −/− mice as described above, infected them with either MSCV-internal ribosome entry site (IRES)-mCherry or MSCV-MYC-IRESmCherry retroviruses and then transplanted them into male and female NRG (NOD.Cg-Rag1 tm1Mom Il2rg tm1Wjl/SzJ) mice (the Jackson Laboratory). We assessed T cell lineage reconstitution 3 weeks after transplant in peripheral blood by flow cytometry quantification of cells stained with specific antibodies against CD4-APC (1:400, RM4-5, BD Pharmingen) and CD8-FITC (1:200, 53-6.7, BD Pharmingen) in a BD LSRFortessa flow cytometer (BD Biosciences) using FACSDiva software (BD Biosciences).
Flow cytometry analysis of Myc expression. We collected cells from the thymi of 6-week-old male and female wild-type and N-Me knockout mice and performed surface membrane stainings using the following antibodies: CD3-Alexa Fluor 488 (1:100, 145-1211, BD Pharmingen), CD8a-PE-Cy7 (1:500, 53-6.7, eBioscience), CD44-PerCP-Cy5.5 (1:400, IM7, eBioscience), CD25-APC-Cy7 Microarray gene expression profiling. We isolated and snap froze spleen samples from N-Me conditional knockout NOTCH-induced T-ALL-bearing mice 40 h after treatment with vehicle only (corn oil, C8267, Sigma-Aldrich) or tamoxifen (T5648, Sigma-Aldrich; 3 mg per mouse in corn oil) administered by intraperitoneal injection. RNA was isolated, labeled and hybridized to the npg
